Reporters.io
Michael Gibney
Pharma Voice
Profile
Contacts
Recent Articles on Subject
1
Michael Gibney
Pharma Voice
Gilead eyes ‘ending the HIV epidemic’ via incremental progress
- 9 days ago
A new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill
- 10 days ago
Has pharma emerged from the ‘age of uncertainty’?
- 11 days ago
As feds crack down on PBMs for drug costs, Big Pharma could lose some of the heat
- 16 days ago
The FDA pushes concrete plans to further diversity in clinical trials
- 19 days ago
In the rapidly shrinking COVID market, this company still sees opportunity
- 24 days ago
How BeiGene is taking on established blockbusters with an expanding blood cancer arsenal
- 25 days ago
Protein power: a biotech mining viruses to fight disease
- 26 days ago
Don’t call it a comeback: Biotech’s CNS resurgence forges Big Pharma connections
- 30 days ago
After 33 years, Geron’s first approval marks a turn in Nobel-winning science
- about 1 month ago
Can Moderna’s COVID-flu combo shot improve flagging vaccination rates?
- about 1 month ago
Avoiding the pharma ‘junk pile’ with launch readiness, pipeline rigor and ‘quick kills’
- about 1 month ago
Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for now
- about 1 month ago
As Big Pharma places bigger bets on ADCs, here’s where the field is headed next
- about 2 months ago
A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myers
- about 2 months ago
AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets
- 2 months ago
Drug shortages, cost concerns and iffy access — how DTC and telehealth could even the playing field
- 2 months ago
3 up-and-coming US biotech hotspots
- 2 months ago
Why AlphaFold 3 is stirring up so much buzz in pharma
- 2 months ago
$4M+ gene therapies? How payers can adapt to a new reality of pricey ‘cures’
- 3 months ago
Now a biopharma powerhouse, Vertex’s R&D bedrock could deliver tomorrow’s blockbusters
- 3 months ago
How pharma’s surging M&A is impacting the industry’s tech sector
- 4 months ago
Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future
- 4 months ago
With an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition
- 4 months ago
A dementia-focused VC digs past anti-amyloid for neuroscience diamonds in the rough
- 4 months ago
With a rise in animal-human organ transplants, a drugmaker aims for a new standard of care
- 4 months ago
‘The heart is back,’ says Cardior CEO — Novo’s $1B+ deal rejuvenates a stale field
- 4 months ago
Alnylam turns to genealogy to find rare disease patients through family trees
- 4 months ago
Who’s getting left behind in the weight loss bonanza?
- 4 months ago
An ocean of answers in a single cell — how proteomics can lead to better drugs
- 4 months ago
As investors ‘lose trust’ in pharma’s business model, focused M&A strategies can help
- 4 months ago
Ex-Novartis exec sets out to create ‘Apple of AI’
- 4 months ago
Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake
- 4 months ago
The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs
- 5 months ago
J&J’s growing rare disease focus brings a potential multi-use treatment to the table
- 5 months ago
Big hopes for schizophrenia treatment rely on a deep pipeline of new approaches
- 5 months ago
HIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure
- 5 months ago
Biogen partner NeuroSense seeks a role in the ALS revolution
- 5 months ago
Can a top scientist and Moderna co-founder change the CRO game?
- 5 months ago
AbbVie CEO Richard Gonzalez leaves a divisive Humira legacy and lasting impact on pharma
- 5 months ago
Biden or Trump: How deeply will 2024’s election outcome impact pharma?
- 5 months ago
The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround
- 5 months ago
Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps
- 6 months ago
‘Beginning of the end’ for small molecules? VCs brace for Medicare investment gap
- 6 months ago
King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way
- 6 months ago
J&J’s 2024 strategy will focus on newer meds to offset Stelara’s patent cliff
- 6 months ago
How to make 2024 a banner year for biopharma, despite the headwinds
- 6 months ago
4 big FDA approval dates to watch in 2024
- 7 months ago
One biotech’s 3 gene therapy hurdles: delivery, delivery and delivery
- 7 months ago
Pharma’s financial market will be a tale of two cities in 2024
- 7 months ago